IONIS PHARMACEUTICALS INC
For the period ended Jun 5, 2025. Filed Apr 25, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 5, 2025 · Filed Apr 25, 2025
Contents
Appendix BB-1
Appendix B
Reconciliation of GAAP to Non-GAAP Basis
As illustrated in the table below, non-GAAP research, development and patent expenses, non-GAAP selling, general and administrative expenses, non-GAAP operating expenses, non-GAAP loss from operations, and non-GAAP net loss were adjusted from GAAP to exclude compensation expense related to equity awards and the related tax effects. Compensation expense related to equity awards are non-cash. These measures are provided as supplementary information and are not a substitute for financial measures calculated in accordance with GAAP. Ionis reports these non-GAAP results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further, the presentation of Ionis’ non-GAAP results is consistent with how Ionis’ management internally evaluates the performance of its operations.
IONIS PHARMACEUTICALS, INC.
Reconciliation of GAAP to Non-GAAP Basis:
Condensed Consolidated Operating Expenses, Loss From Operations, and Net Loss
(In Millions)
| Three months endedDecember 31, · Year endedDecember 31, | ||||
|---|---|---|---|---|
| 2024 · 2023 · 2024 · 2023 | ||||
| (unaudited) | ||||
| As reported research, development and patent expenses according to GAAP | $245 | $257 | $902 | $900 |
| Excluding compensation expense related to equity awards | (25) | (20) | (92) | (78) |
| Non-GAAP research, development and patent expenses | $220 | $237 | $810 | $822 |
| As reported selling, general and administrative expenses according to GAAP | $88 | $71 | $267 | $232 |
| Excluding compensation expense related to equity awards | (11) | (6) | (37) | (27) |
| Non-GAAP selling, general and administrative expenses | $77 | $65 | $230 | $205 |
| As reported operating expenses according to GAAP | $337 | $331 | $1,180 | $1,141 |
| Excluding compensation expense related to equity awards | (36) | (26) | (130) | (106) |
| Non-GAAP operating expenses | $301 | $305 | $1,050 | $1,035 |
| As reported loss from operations according to GAAP | ($110) | ($6) | ($475) | ($353) |
| Excluding compensation expense related to equity awards | (36) | (26) | (130) | (106) |
| Non-GAAP loss from operations | ($74) | $20 | ($345) | ($247) |
| As reported net loss according to GAAP | ($104) | ($9) | ($454) | ($366) |
| Excluding compensation expense related to equity awards and related tax effects | (36) | (26) | (130) | (106) |
| Non-GAAP net loss | ($68) | $17 | ($324) | ($260) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.